X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
edoxaban (823) 823
rivaroxaban (483) 483
index medicus (478) 478
apixaban (473) 473
dabigatran (449) 449
warfarin (421) 421
humans (375) 375
anticoagulants (319) 319
atrial fibrillation (318) 318
administration, oral (211) 211
stroke (198) 198
cardiac & cardiovascular systems (186) 186
venous thromboembolism (182) 182
anticoagulants - therapeutic use (156) 156
peripheral vascular disease (156) 156
hematology (154) 154
thromboembolism (152) 152
factor xa inhibitor (145) 145
male (139) 139
safety (133) 133
atrial-fibrillation (131) 131
anticoagulants - adverse effects (130) 130
atrial fibrillation - drug therapy (128) 128
anticoagulants - administration & dosage (127) 127
prevention (125) 125
female (118) 118
pharmacology & pharmacy (106) 106
anticoagulation (105) 105
aged (102) 102
stroke prevention (102) 102
stroke - prevention & control (98) 98
risk factors (96) 96
dabigatran etexilate (95) 95
hemorrhage - chemically induced (94) 94
treatment outcome (94) 94
analysis (93) 93
atrial fibrillation - complications (93) 93
bleeding (91) 91
pharmacokinetics (91) 91
direct oral anticoagulants (86) 86
oral anticoagulants (86) 86
risk (85) 85
management (82) 82
efficacy (79) 79
middle aged (78) 78
pyridines - administration & dosage (78) 78
pyridines - therapeutic use (78) 78
thiazoles - administration & dosage (78) 78
thiazoles - therapeutic use (77) 77
thrombin (77) 77
thrombosis (76) 76
medicine & public health (72) 72
therapy (69) 69
medicine, general & internal (68) 68
cardiology (66) 66
pyridines - adverse effects (66) 66
thiazoles - adverse effects (66) 66
factor xa inhibitors - therapeutic use (65) 65
blood coagulation - drug effects (64) 64
warfarin - therapeutic use (64) 64
cardiac arrhythmia (63) 63
patients (63) 63
care and treatment (62) 62
stroke - etiology (62) 62
drug therapy (59) 59
venous thromboembolism - drug therapy (58) 58
abridged index medicus (55) 55
clinical trials (55) 55
hemorrhage (54) 54
factor xa inhibitors (52) 52
mortality (52) 52
review (51) 51
antithrombotic therapy (50) 50
factor xa inhibitors - administration & dosage (50) 50
direct thrombin inhibitor (49) 49
pharmacodynamics (48) 48
pulmonary embolism (48) 48
randomized controlled trials as topic (46) 46
factor xa inhibitors - adverse effects (45) 45
internal medicine (44) 44
anticoagulant (43) 43
fibrillation (43) 43
warfarin - adverse effects (43) 43
anticoagulants - pharmacokinetics (42) 42
metaanalysis (42) 42
nonvalvular atrial-fibrillation (42) 42
reversal (41) 41
deep-vein thrombosis (40) 40
pyridines - pharmacokinetics (40) 40
thiazoles - pharmacokinetics (40) 40
adult (39) 39
cancer (39) 39
dose-response relationship, drug (39) 39
prothrombin complex concentrate (39) 39
thromboprophylaxis (39) 39
animals (38) 38
cardiovascular diseases (38) 38
health aspects (38) 38
pharmacology (38) 38
pyrazoles - therapeutic use (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (764) 764
German (25) 25
French (13) 13
Spanish (9) 9
Japanese (7) 7
Hungarian (6) 6
Russian (5) 5
Italian (3) 3
Portuguese (3) 3
Czech (2) 2
Korean (2) 2
Polish (2) 2
Chinese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2018, Volume 36, Issue 20, pp. 2017 - 2023
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment... 
ANTICOAGULANTS | ONCOLOGY | WARFARIN | THROMBOSIS | RIVAROXABAN | PREVENTION | EDOXABAN | K-ANTAGONIST | BLEEDING COMPLICATIONS
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2018, Volume 72, Issue 13, pp. 1466 - 1475
There is limited information about the use of antithrombotic therapies and outcomes of Latin American (LatAm) subjects with atrial fibrillation. The global... 
atrial fibrillation | edoxaban | anticoagulation | Latin America
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2018, Volume 72, Issue 8, pp. 838 - 853
It is unclear whether edoxaban shows better risk reduction of ischemic stroke, bleeding, and all-cause mortality than warfarin in Asian patients with... 
anticoagulants | atrial fibrillation | Asian | stroke | edoxaban | warfarin
Journal Article
Intervencni a Akutni Kardiologie, ISSN 1213-807X, 2018, Volume 17, Issue 3, pp. 169 - 172
Journal Article
Vascular Health and Risk Management, ISSN 1178-2048, 08/2016, Volume 2016, Issue Issue 1, pp. 329 - 335
Katherine V Hurst, John Matthew O'Callaghan, Ashok Handa Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK Abstract: The new... 
Edoxaban | stroke management | venous thromboembolism
Journal Article
Circulation Journal, ISSN 1346-9843, 05/2019, Volume 83, Issue 6, pp. 1394 - 1404
Background: ETNA-VTE-Japan is an ongoing prospective observational study conducted as part of a postmarketing observational study to investigate the safety and... 
Edoxaban | Postmarketing observational study | Bleeding adverse events | Japan | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | XA INHIBITOR EDOXABAN | ANTAGONIST ORAL ANTICOAGULANTS | BLEEDING EVENTS | APIXABAN
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2018, Volume 39, Issue 19, pp. 1657 - 1660
Journal Article
日本血栓止血学会誌, ISSN 0915-7441, 2017, Volume 28, Issue 1, pp. 50 - 54
Abstract: Background: The direct anti-Xa agent edoxaban was approved in September 2014 as an alternative to warfarin for treatment of venous thromboembolism... 
anticoagulation, edoxaban, venous thromboembolism
Journal Article
AMERICAN HEART JOURNAL, ISSN 0002-8703, 02/2016, Volume 172, pp. 144 - 151
Background Edoxaban is a specific anti-Xa inhibitor that, in comparison to warfarin, has been found to be noninferior for the prevention of stroke or systemic... 
PREDICTING STROKE | INHIBITOR EDOXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 10/2013, Volume 2, Issue 4, pp. 358 - 366
Background Edoxaban is an oral, once‐daily, direct factor Xa inhibitor under investigation for stroke prevention in patients with atrial fibrillation and for... 
pharmacokinetics | factor Xa | quinidine | bioavailability | edoxaban | Factor Xa | Bioavailability | Edoxaban | Pharmacokinetics | Quinidine
Journal Article
Medicina Clinica, ISSN 0025-7753, 09/2018, Volume 151, Issue 5, pp. 198 - 206
Vitamin K antagonists were the only choice for chronic oral anticoagulation for more than half a century. Over the past few years, direct oral anticoagulants... 
Anticoagulant treatment | Rivaroxaban | Dabigatran etexilate | Edoxaban | Vitamin K antagonists | Apixaban
Journal Article
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, ISSN 2160-7648, 10/2013, Volume 2, Issue 4, pp. 358 - 366
Background: Edoxaban is an oral, once-daily, direct factor Xa inhibitor under investigation for stroke prevention in patients with atrial fibrillation and for... 
quinidine | bioavailability | pharmacokinetics | PHARMACOLOGY & PHARMACY | factor Xa | edoxaban
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2017
Direct oral anticoagulants (DOACs) were developed to compensate for the demerits of warfarin. In Japan, three factor Xa inhibitors are used for the treatment... 
Rivaroxaban | Direct oral anticoagulant | Edoxaban | Apixaban
Journal Article
Internal Medicine, ISSN 0918-2918, 2017
A 39-year-old man with nephrotic syndrome was admitted due to right dorsal pain. Contrast-enhanced CT led to a diagnosis of renal vein thrombosis and segmental... 
renal vein thrombosis | edoxaban | nephrotic syndrome
Journal Article
Circulation Journal, ISSN 1346-9843, 2016
Background:The distribution of anti-factor Xa activity (AXA) values in non-valvular atrial fibrillation (NVAF) patients on edoxaban therapy has not been fully... 
Edoxaban | Anti-factor Xa activity | Atrial fibrillation
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2019, Volume 40, Issue 19, pp. 1528 - 1530
This editorial refers to 'Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with... 
EDOXABAN VS. WARFARIN | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | RACIAL/ETHNIC DIFFERENCES | ATRIAL-FIBRILLATION
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.